A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.
Also called NCT01225081
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 152 participants
- Sponsor
- Registry
-
NCT01225081
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01225081. Randomized; quadruple masking; primary purpose treatment. Start 2010-09-15 (actual); primary completion 2012-04-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- ipragliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct01225081- Content hash
0434b9af3622ad9021bb9e02be4e9ee755f2133ee478d16ae95d471be8bc0eaf